Follow the Advaxis, Inc. stock price and the full management transaction log of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Market capitalisation: €2.2bn. The latest transaction was reported on 1 February 2016 (Attribution). Among the most active insiders: O'Connor Daniel. Every trade is accessible without an account.
20
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
2 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Advaxis, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$59.30.
Fundamental score
Ranked 24,855 of 29,063 companies
26.3
score / 100
Value
23
Quality
30
FCF yld-4.0%
Earn yld-5.1%
EV/EBITDA·
ROE-40%
Gross mgn36%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Advaxis, Inc. es una empresa biofarmacéutica que desarrolla tratamientos de inmunoterapia para el cáncer. Se enfoca en el uso de tecnología de ADN para estimular el sistema inmunológico.